The Poly-Pharmacology of S-4321, a Dual Cell -Bi- Directional PD-1 Agonist for the Treatment of Autoimmune & Inflammatory Diseases
Time: 1:30 pm
day: Day 2 Treg Modulators Track PM
Details:
- Discussing the tole of inhibitory receptor in the maintenance of immune tolerance
- Highlight ongoing research initiatives on dual cell bidirectional PD-1 agonist
- Explore the intersection of Treg biology and PD-1 agonism
